{"generic":"Diatrizoate Meglumine","drugs":["Cystografin","Cystografin-Dilute","Diatrizoate Meglumine","Hypaque Meglumine","Hypaque-Cysto","Reno-30","Reno-60","Reno-Dip"],"mono":{"0":{"id":"3shws0","title":"Generic Names","mono":"Diatrizoate Meglumine"},"1":{"id":"3shws1","title":"Dosing and Indications","sub":{"0":{"id":"3shws1b4","title":"Adult Dosing","mono":"<ul><li><b>Arteriography, Peripheral:<\/b> (Reno-60(R)) 20 to 40 mL single dose, rapidly injected into the femoral or subclavian artery by PERCUTANEOUS or operative method to visualize an entire extremity; 10 to 20 mL to visualize upper or lower half of the extremity<\/li><li><b>Arteriography, Peripheral:<\/b> (Hypaque(TM)) 20 to 40 mL introduced into the larger peripheral arteries by PERCUTANEOUS or operative methods<\/li><li><b>Arthrography:<\/b> (Hypaque(TM) or Reno-60(R)) knee, 5 to 15 mL injection; shoulder or hip, 5 to 10 mL injection; temporomandibular, 0.5 mL; other, 1 to 4 mL injection; a 1 to 2 mL test dose sometimes used<\/li><li><b>CAT scan - whole body, Contrast enhancement:<\/b> (Reno-dip(R)) 300 mL by IV infusion over approximately 20 minutes; 150 mL may be infused immediately before scanning<\/li><li><b>CAT scan - whole body, Contrast enhancement:<\/b> (Ren-60(R)) 100 mL rapid IV (within approximately 1 minute) bolus injection<\/li><li><b>Cervical discography:<\/b> (Hypaque(TM) or Reno-60(R)) up to 0.5 mL injected slowly; MAX 2 mL into any one disk<\/li><li><b>CT of head, Contrast enhancement:<\/b> (Hypaque(TM)) 50 to 100 mL bolus IV injection or up to 150 mL by infusion; rate of injection depends on the pathology<\/li><li><b>CT of head, Contrast enhancement:<\/b> (Reno-60(R)) 50 to 150 mL IV<\/li><li><b>CT of head, Contrast enhancement:<\/b> (Reno-dip(R)) 2 mL\/pound of body weight by IV drip over 8 minutes or longer<\/li><li><b>Head angiography:<\/b> (Hypaque(TM)) 8 to 12 mL rapidly injected at a rate not exceeding the normal flow in the carotid artery (about 5 mL per second); repeated as indicated<\/li><li><b>Head angiography:<\/b> (Reno-60(R)) 10 mL rapidly injected by PERCUTANEOUS or operative method; repeated as indicated<\/li><li><b>Intraoperative cholangiogram, Direct:<\/b> (Hypaque(TM)) 10 to 25 mL of a 30% to 60% solution injected or instilled slowly without undue pressure into the cystic duct or common bile duct<\/li><li><b>Intraoperative cholangiogram, Direct:<\/b> (Reno-60(R)) 10 to 25 mL IV instilled slowly through the stump of the cystic duct or directly into the choledochal lumen, repeated if needed<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (Hypaque(TM)) 30 to 60 mL by either direct IV bolus injection or IV drip infusion or IM or SubQ, injected in 1 to 3 min; may use 20 mL in persons of slight build<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (Reno-60(R)) 25 mL direct IV injection (range, 25 to 50 mL) or drip infusion with dose calculated on the basis of 1 mL\/pound of body weight diluted with an equal volume of sterile water for injection; the diluted preparation (30%) administered by IV infusion at a rate of 40 mL\/minute (total volume not to exceed 300 mL)<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (Reno-60(R)) IV doses (25 mL) divided and used IM, administered bilaterally into the gluteal muscles<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (Reno-dip(R)) 2 mL\/Ib of body weight by continuous IV infusion over 8 min or longer<\/li><li><b>Lumbar discography:<\/b> (Hypaque(TM) or Reno-60(R)) up to 1 mL (rarely 2 mL) injected slowly; MAX 2 mL into any one disk<\/li><li><b>Percutaneous transhepatic cholangiogram:<\/b> (Hypaque(TM) or Reno-60(R)) 20 to 40 mL slowly injected into the biliary duct under very slight pressure, range, 10 to 60 mL; if a duct is not located, small doses of 1 to 2 mL injected into the liver as the needle is gradually withdrawn, until a duct is visualized by x-ray<\/li><li><b>Postoperative cholangiography - T tube cholangiogram:<\/b> (Ren-60(R)) 10 to 25 mL injected through an in-place T-tube, performed 8 to 10 days after operation<\/li><li><b>Retrograde cystourethrogram:<\/b> (Hypaque-cysto(TM)) 200 to 300 mL (rarely, 600 mL) instilled without force into the bladder to slightly less than capacity; may vary from patient to patient<\/li><li><b>Retrograde cystourethrogram:<\/b> (Cystografin(R)) 25 to 300 mL instilled into the bladder to capacity without excessive pressure; greater than 300 mL depending on bladder capacity<\/li><li><b>Retrograde pyelogram:<\/b> (Reno-30(R)) 15 mL for unilateral and appropriately increased volumes for bilateral pyelograms; approximately 5 to 6 mL generally required per exposure<\/li><li><b>Splenoportogram by splenic arteriography:<\/b> (Hypaque(TM) or Reno-60(R)) 20 to 25 mL of 50% solution rapidly injected; initially inject a small pilot dose to confirm splenic entry<\/li><li><b>Venography:<\/b> (Hypaque(TM)) 10 to 20 mL by PERCUTANEOUS or operative methods to visualize veins in the extremities<\/li><li><b>Venography:<\/b> (Reno-dip(R)) 50 to 100 mL as a bolus IV injection or by steady drip infusion; total dose, 100 to 300 mL per lower extremity<\/li><li><b>Venography:<\/b> (Reno-60(R)) 10 mL per upper extremity as a single dose by rapid PERCUTANEOUS injection into any convenient superficial vein of the forearm or hand<\/li><li><b>Venography:<\/b> (Reno-60(R)) 20 to 40 mL per lower extremity; injected rapidly into a superficial vein on the lateral side of the foot; MAX 100 mL per lower extremity<\/li><li><b>Venography:<\/b> (Reno-60(R)) 50 mL or more to visualize the iliac vein, extensive varicosities or large veins<\/li><\/ul>"},"1":{"id":"3shws1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Arthrography:<\/b> (Hypaque(TM) or Reno-60(R)) proportionally less than adult doses (knee, 5 to 15 mL injection; shoulder or hip, 5 to 10 mL injection; temporomandibular, 0.5 mL; other, 1 to 4 mL injection)<\/li><li><b>CT of head, Contrast enhancement:<\/b> (Hypaque(TM) or Reno-60(R)) proportional to adults, based on weight<\/li><li><b>Head angiography:<\/b> (Hypaque(TM) or Reno-60(R)) less than the 10 mL adult dose rapidly injected by PERCUTANEOUS or operative method; use dose in proportion to weight<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (under 2 years of age, up to 10 pound of body weight) (Hypaque(TM)) 5 to 10 mL by either direct IV bolus injection or IV drip infusion or IM or SubQ, injected in 1 to 3 min; may use compression<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (under 2 years of age, 10 to 30 pound of body weight) (Hypaque(TM)) 10 to 15 mL by either direct IV bolus injection or IV drip infusion or IM or SubQ, injected in 1 to 3 min; may use compression<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (2 to 12 years of age, 30 to 60 pound of body weight) (Hypaque(TM)) 15 to 30 mL by either direct IV bolus injection or IV drip infusion or IM or SubQ, injected in 1 to 3 min; may use compression<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (2 to 12 years of age, over 60 pound of body weight) (Hypaque(TM)) 30 mL by either direct IV bolus injection or IV drip infusion or IM or SubQ, injected in 1 to 3 min; may use compression<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (older than 12 years of age) (Hypaque(TM)) 30 to 60 mL by either direct IV bolus injection or IV drip infusion or IM or SubQ, injected in 1 to 3 min; may use compression; may use 20 mL in persons of slight build<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (under 6 months of age) (Reno-60(R)) 5 mL by direct IV injection or drip infusion<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (6 to 12 months of age) (Reno-60(R)) 8 mL by direct IV injection or drip infusion<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (1 to 2 years of age) (Reno-60(R)) 10 mL by direct IV injection or drip infusion<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (2 to 5 years of age) (Reno-60(R)) 12 mL by direct IV injection or drip infusion<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (5 to 7 years of age) (Reno-60(R)) 15 mL by direct IV injection or drip infusion<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (8 to 10 years of age) (Reno-60(R)) 18 mL by direct IV injection or drip infusion<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (11 to 15 years of age) (Reno-60(R)) 20 mL by direct IV injection or drip infusion<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (16 years and older) (Reno-60(R)) 25 to 50 mL by direct IV injection or drip infusion<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (Reno-60(R)) IV doses divided and used IM, administered bilaterally into the gluteal muscles<\/li><li><b>Retrograde cystourethrogram:<\/b> (Hypaque-cysto(TM)) (3 to 5 years of age) 150 to 180 mL instilled without force into the bladder to slightly less than capacity; bladder capacity at birth 20 to 50 mL; increases about 400% in the first year; may vary from patient to patient<\/li><li><b>Retrograde cystourethrogram:<\/b> (Hypaque-cysto(TM)) (older than 8 years) in the low adult range instilled without force into the bladder to slightly less than capacity; may vary from patient to patient<\/li><li><b>Retrograde pyelogram:<\/b> (Reno-30(R)) proportionately smaller than the adult dose (15 mL for unilateral and appropriately increased volumes for bilateral pyelograms; approximately 5 to 6 mL generally required per exposure)<\/li><li><b>Venography:<\/b> (Reno-dip(R)) dose proportional to adults, based on weight<\/li><\/ul>"},"3":{"id":"3shws1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Arteriography, Peripheral<\/li><li>Arthrography<\/li><li>CAT scan - whole body, Contrast enhancement<\/li><li>Cervical discography<\/li><li>CT of head, Contrast enhancement<\/li><li>Head angiography<\/li><li>Intraoperative cholangiogram, Direct<\/li><li>Intravenous pyelogram, Excretory urography<\/li><li>Lumbar discography<\/li><li>Percutaneous transhepatic cholangiogram<\/li><li>Postoperative cholangiography - T tube cholangiogram<\/li><li>Retrograde cystourethrogram<\/li><li>Retrograde pyelogram<\/li><li>Splenoportogram by splenic arteriography<\/li><li>Venography<\/li><\/ul>"}}},"3":{"id":"3shws3","title":"Contraindications\/Warnings","sub":[{"id":"3shws3b9","title":"Contraindications","mono":"<ul><li>when used as recommended, there are no absolute contraindication<\/li><li>administration into subarachnoid space; even small amounts may cause convulsions and death (Hypaque(TM))<\/li><li>anuria; urography is contraindicated<\/li><li>coagulation defects, prolonged prothrombin times (below 50%), or significant thrombocytopenia; percutaneous transhepatic cholangiography or splenoportography are contraindicated <\/li><li>dehydrated azotemic patients; urography and large-dose vascular procedures are contraindicated (Hypaque(TM))<\/li><li>hypersensitivity to diatrizoic acid salts<\/li><li>intrathecal procedures<\/li><li>myelography or examination of dorsal cysts or sinuses (Hypaque(TM))<\/li><\/ul>"},{"id":"3shws3b10","title":"Precautions","mono":"<ul><li>abdominal compression; increased risk of neurologic complications (including paraplegia) when Hypaque(TM) is administered with aortography<\/li><li>aortic-iliac or femoral artery bed obstruction; increased risk of neurologic complications (including paraplegia) when Hypaque(TM) is administered with aortography<\/li><li>aortic circulation, slowed; increased risk of muscle spasm when Hypaque(TM) is administered with aortography<\/li><li>arterial hypertension, severe; increased risk when Reno-60(R) is administered with cerebral angiography<\/li><li>arteriosclerosis, advanced; risk when Reno-60(R)  is administered with cerebral angiography<\/li><li>ascending infection with severe ischemia; risk associated with Hypaque(TM)  administration during peripheral angiography<\/li><li>blood pressure, low or high; increased risk of neurologic complications (including paraplegia) with Hypaque(TM) administration during aortography<\/li><li>brain metastases; increased risk of seizures when high doses of ionic contrast media are given during CT scan (Hypaque(TM))<\/li><li>bronchial asthma or allergy, personal or family history; increased risk of drug hypersensitivity reaction<\/li><li>cardiac decompensation; increased risk with cerebral angiography (Reno-60(R)) <\/li><li>cerebral embolism, recent; increased risk with cerebral angiography (Reno-60(R)) <\/li><li>concomitant general anesthesia; may increase risk of adverse effects due to reduced cardiac output and increased duration of contrast agent exposure (Hypaque(TM))<\/li><li>concomitant hepatic and renal disease, severe; risk with urography<\/li><li>concomitant vasopressor use; increased risk of neurologic complications, including paraplegia, with aortography administration (Hypaque(TM))<\/li><li>congestive heart failure; risk with injection of urographic agents due to the transitory increase in the circulatory osmotic load (Hypaque(TM))<\/li><li>debilitated, severely; risk with cerebral angiography, and risk of thrombosis with percutaneous administration techniques (Reno-60(R)) <\/li><li>diabetes; preparatory dehydration for angiography and CT procedures may contribute to renal failure (Hypaque(TM)) <\/li><li>diabetes with diabetic neuropathy; risk of acute renal failure following urographic procedures<\/li><li>elderly patients; preparatory dehydration for angiography and CT procedures may contribute to renal failure (Hypaque(TM)) <\/li><li>elderly patients with renal disease, or other susceptible nondiabetic patients; risk of acute renal failure following urographic procedures<\/li><li>extreme age; increased risk with cerebral angiography (Reno-60(R))<\/li><li>homocystinuria, pre-existing; increased risk of inducing thrombosis and embolism with angiography (Hypaque(TM))<\/li><li>hypertension, marked; risk of thrombosis with percutaneous administration techniques (Reno-60(R))<\/li><li>hyperthyroidism; or patients with an autonomously functioning thyroid nodule; risk of thyroid storm following intravascular use (Hypaque(TM))<\/li><li>hypotension; increased risk with peripheral arteriography with intra-arterial (brachial) injections (Reno-60(R))<\/li><li>infants and young children; preparatory dehydration for angiography and CT procedures may contribute to renal failure; increased risk of convulsions, especially with repeated injections (Hypaque(TM))<\/li><li>liver or biliary disease; increased renal toxicity following oral cholecystography (RENO-60(R))<\/li><li>low-injection sites (L2 to L3); increased risk of neurologic complications, including paraplegia, with aortography (Hypaque(TM))<\/li><li>migraine, during or soon after an attack; increased risk of ischemic complications with cerebral angiography (Hypaque(TM))<\/li><li>multiple myeloma; precipitation of myeloma protein in renal tubules may cause anuria, leading to progressive uremia, renal failure, and death<\/li><li>pheochromocytoma, known or suspected; risk of hypertensive crisis<\/li><li>renal disease, severe; increased risk of adverse effects (Hypaque(TM))<\/li><li>renal insufficiency, pre-existing; preparatory dehydration for angiography and CT procedures may contribute to renal failure (Hypaque(TM))<\/li><li>renal transplant; use caution when performing excretory urography immediately following surgery (Hypaque(TM))<\/li><li>sensitivity to iodine or other contrast agent, history<\/li><li>sickle cell disease, homozygous; intravenous or intra-arterial administration may precipitate sickling<\/li><li>spinal anesthesia; increased risk of neurologic complications, including paraplegia, with aortography administration (Hypaque(TM)) <\/li><li>subarachnoid hemorrhage; risk of clinical deterioration, including convulsions and death<\/li><li>thromboangiitis obliterans;  risk associated with peripheral arteriography; may induce a severe arterial or venous spasm (Hypaque(TM)) <\/li><li>vascular disease; increased risk for subcutaneous extravasation and sloughing of skin, especially in poorly vascularized areas (eg; dorsum of the foot or hand) (Hypaque(TM)) <\/li><li>vascular disease, advanced; preparatory dehydration for angiography and CT procedures may contribute to renal failure (Hypaque(TM))<\/li><\/ul>"},{"id":"3shws3b11","title":"Pregnancy Category","mono":"Diatrizoate: C (FDA)<br\/>"},{"id":"3shws3b12","title":"Breast Feeding","mono":"<ul><li>Diatrizoate: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Diatrizoate: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"3shws4","title":"Drug Interactions","sub":[{"id":"3shws4b13","title":"Contraindicated","mono":"<ul>Metformin (theoretical)<\/ul>"},{"id":"3shws4b14","title":"Major","mono":"<ul>Propranolol (theoretical)<\/ul>"}]},"5":{"id":"3shws5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Vasodilatation (49%)<\/li><li><b>Dermatologic:<\/b>Flushing, Injection site pain (about 12%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (6%), Taste sense altered (11%), Vomiting (3%)<\/li><li><b>Neurologic:<\/b>Dizziness (5%), Paresthesia (6%)<\/li><li><b>Renal:<\/b>Hypokalemic nephropathy, Osmotic nephrosis after excretory urography (23% (excretory urography))<\/li><li><b>Respiratory:<\/b>Cough (2%), Rhinitis (1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest (less than 1%), Shock (0.005%), Thrombophlebitis, Ventricular fibrillation (less than 1%)<\/li><li><b>Dermatologic:<\/b>Necrosis \/ ulceration of skin due to extravasation of drug (1%)<\/li><li><b>Hematologic:<\/b>Thrombocytopenia (less than 1%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Seizure (less than 1%)<\/li><li><b>Renal:<\/b>Renal failure (less than 1%)<\/li><li><b>Respiratory:<\/b>Bronchospasm (less than 1%), Cardiorespiratory arrest (less than 1%), Pulmonary edema (less than 1%)<\/li><\/ul>"},"6":{"id":"3shws6","title":"Drug Name Info","sub":{"0":{"id":"3shws6b17","title":"US Trade Names","mono":"<ul><li>Cystografin<\/li><li>Cystografin-Dilute<\/li><li>Hypaque Meglumine<\/li><li>Hypaque-Cysto<\/li><li>Reno-30<\/li><li>Reno-60<\/li><li>Reno-Dip<\/li><\/ul>"},"2":{"id":"3shws6b19","title":"Class","mono":"Radiological Ionic Contrast Media<br\/>"},"3":{"id":"3shws6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"3shws6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"3shws7","title":"Mechanism Of Action","mono":"The use of diatrizoate is not based on its pharmacologic properties, but on its distribution and elimination from the body. The iodine content of a contrast media is the most important factor, since this component is responsible for the absorption of radiation and the degree of opacification.  The high atomic weight of iodine contributes sufficient x-radiation attenuation to impart radiographic contrast with surrounding tissue.  Diagnostic radiopaque agents have few known pharmacological effects.<br\/>"},"8":{"id":"3shws8","title":"Pharmacokinetics","sub":{"1":{"id":"3shws8b24","title":"Distribution","mono":"Protein binding: 0% to 10% bound to serum albumin <br\/>"},"2":{"id":"3shws8b25","title":"Metabolism","mono":"not metabolized <br\/>"},"3":{"id":"3shws8b26","title":"Excretion","mono":"<ul><li>Fecal: (intravenous), less than 2%<\/li><li>Renal: (intravenous), 12% within 10 minutes, 38% at 60 minutes, 45% at 3 hours, and 94% to 100% at 24 hours excreted unchanged<\/li><\/ul>"},"4":{"id":"3shws8b27","title":"Elimination Half Life","mono":"Adults: (intravenous), 120 min <br\/>"}}},"9":{"id":"3shws9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>do NOT administer by intrathecal route<\/li><li>do NOT administer the diatrizoate meglumine 30% (Hypaque-Cysto(TM) or Reno-30(R)) by intravascular route<\/li><li>solution should be at body temperature when injected; may need to be warmed<\/li><li>if crystallization occurs, place the vial in a water bath at 40 to 50 degrees C and shake it gently for 2 to 3 minutes or until solids redissolve; discard the vial if particles still persist<\/li><li>solution may be autoclaved once<\/li><li>do not contaminate catheters, syringes, needles, and contrast media with glove powder or cotton fibers<\/li><li>discard any unused portion<\/li><li>(angiography), flush the catheter frequently with heparinized saline solutions; use plastic syringes in place of glass to decrease the likelihood of in vitro clotting<\/li><li>(cervical discography), use 2-needle technique to avoid the rupture of the disk<\/li><li>(drip infusion pyelography), dose of diatrizoate meglumine 60% (Reno-60(R)) calculated on the basis of 1 mL\/pound of body weight, diluted with an equal volume of sterile water for injection; the diluted preparation (30%) (Reno-60(R)) administered by IV infusion through a large bore (17 or 18 gauge needle)<\/li><li>(operative and T-tube cholangiography), inject the agent very slowly to prevent extravasation<\/li><li>(percutaneous transhepatic cholangiography), aspirate as much of the contrast agent as possible after the procedure to reduce to potential of bile leakage and peritonitis<\/li><li>(splenoportography), avoid manipulations which would prolong the time the needle is in the spleen to avoid subcapsular extravasation of agent and bleeding<\/li><li>diatrizoate meglumine 30% (Hypaque-cysto(TM)) may be diluted with sterile water or 5% dextrose solution; a 10% solution is isotonic<\/li><\/ul>"},"10":{"id":"3shws10","title":"Monitoring","mono":"<ul><li>image quality and diagnostic usefulness<\/li><li>vital signs; baseline and then periodically<\/li><li>ECG; baseline and then periodically as clinically indicated<\/li><li>injection site reactions; frequently for any signs of extravasation<\/li><li>renal and hepatic function; baseline and then periodically as clinically indicated<\/li><li>signs and symptoms of iodine or other contrast agents sensitivity; during procedure and then for 30 to 60 minutes after the procedure<\/li><li>signs and symptoms of thrombosis; especially when percutaneous techniques are employed<\/li><li>thyroid function tests (T3 resin uptake and total or free thyroxine (T4) assays); at baseline and after procedure as clinically indicated<\/li><\/ul>"},"11":{"id":"3shws11","title":"How Supplied","mono":"<ul><li><b>Cystografin-Dilute<\/b><br\/>Intravenous Solution: 18 %<br\/><\/li><li><b>Cystografin<\/b><br\/>Intravenous Solution: 30 %<br\/><\/li><\/ul>"},"13":{"id":"3shws13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>Instruct patient to rise slowly from a sitting\/supine position, as drug may cause hypotension.<\/li><li>Drug may cause flushing, nausea, vomiting, fever, chills, headache, edema, urticaria, and rash.<\/li><\/ul>"}}}